Objective: Resource allocation informed by cost-utility analysis requires that the benefits are comparable across patient groups and interventions. One option is to recommend the use of one generic utility measure, but this raises the issue of comparability when the preferred measure is inappropriate or unavailable. Many cancer trials do not include generic measures such as EQ-5D and instead include condition-specific measures and use these to generate utility estimates. We analyse the comparability of generic, condition-specific and mapped utility values for a Multiple Myeloma cancer patient dataset.
Comparison of generic, condition-specific and mapped health state utility values
Donna
Introduction
Resource allocation informed by economic evaluation using cost-utility analysis has become increasingly popular in recent years. This analysis requires that the measures of benefit and cost for each evaluation are comparable both across different patient groups and different interventions. Benefit is measured using quality-adjusted life years (QALYs) which are a measure of both quantity and quality of life. Often generic preference-based measures such as the EQ-5D (1), HUI3 (2) or SF-6D (3;4) are used to calculate the 'Q' component of the QALY. However it is well documented that different generic measures produce different results when applied to the same patient group at the same point in time (5) . This raises issues for comparability, and one solution is to recommend the use of a single measure for all evaluations. This is the approach taken by the National Institute of Health and Clinical Excellence (NICE) (6) where the most commonly used generic measure, EQ-5D, is recommended for use in all technology appraisals. This raises the question of how utility values should be generated if EQ-5D is either unavailable or inappropriate, and the comparability of evaluations undertaken in these circumstances.
Cancer is one condition where it remains unclear whether the generic EQ-5D is appropriate, but is further complicated by the fact that EQ-5D is often unavailable as many cancer trials do not include it. NICE state that if a measure is thought inappropriate empirical evidence should be provided demonstrating why it is inappropriate, covering properties such as content validity, construct validity, responsiveness and reliability. A recent report argues that the EQ-5D may not be sufficiently sensitive to capture changes in health status of cancer patients, as, for example, there is no EQ-5D dimension to specifically capture changes in vitality or energy (7) . However there is little guidance provided by NICE or similar agencies of when a measure can be deemed inappropriate for a patient group or intervention, and this is an area requiring further research and guidance. If EQ-5D is inappropriate, NICE state that other measures can be used (6) .
Clinicians and researchers often choose to include condition-specific profile measures in trials rather than generic preference-based measures such as EQ-5D. Condition-specific profile measures, such as EORTC QLQ-C30 are often included as these capture the effects of interventions across a wide range of relevant symptoms, side effects and aspects of functioning and quality of life and their validity is well established. These profile measures have great clinical utility and are recommended by the US FDA (8) , whereas the EQ-5D is recommended only for economic evaluation and can be viewed as being an additional burden for completion for patients who are very unwell. However these condition-specific profile measures typically provide a description rather than a valuation of health and cannot be used to populate cost-effectiveness models. In recent years there has been a growth in preferencebased measures derived from existing condition-specific measures that enable these measures to be used directly to generate utilities. The EORTC-8D is a recently developed condition-specific preference-based measure derived from EORTC QLQ-C30 for use in cancer patients (9) . This measure allows a utility estimate to be generated for every individual each time the EORTC QLQ-C30 is used and enables the direct estimation of utility without placing any burden on patients to complete an extra measure or additional questions.
Mapping is an alternative method that can be used to obtain utility values when only a condition-specific non-preference-based measure was included in the trial. Mapping applies the statistical relationship between, for example, QLQ-C30 and EQ-5D to obtain predicted EQ-5D values from QLQ-C30 data. This relationship is typically obtained by estimating regressions on a separate dataset which has similar patient characteristics to the trial.
Published mapping algorithms are available that map the condition-specific QLQ-C30 onto EQ-5D, and these algorithms can be applied to the trial dataset to produce EQ-5D estimates.
If EQ-5D is unavailable in a trial, NICE (6) recommend that either mapping or other validated measures are used to produce utility values. NICE stipulate that the mapping must be based on empirical data and the other measures should have valuation methods that are comparable to those used for EQ-5D (MVH tariff) (10) .
A small number of studies have examined the impact of using mapped EQ-5D estimates rather than directly generated EQ-5D utilities, finding different results across studies (11) (12) (13) .
A large number of studies compare the performance of EQ-5D to the other main generic preference-based measures such as SF-6D and HUI2 (see (5) for an overview) but there are few comparisons of condition-specific and generic preference-based measures (see (14) ).
Furthermore as far as the authors are aware no study has examined the comparability of all preferred options for use in technology appraisals to agencies such as NICE; as although EQ-5D is the preferred option, under certain circumstances other generic, condition-specific or mapped EQ-5D utility estimates can be used.
This paper compares utility values generated using the EQ-5D to utilities generated using a condition-specific preference-based measure and mapping for a cancer patient dataset. We compare utility values obtained using: generic preference-based EQ-5D; condition-specific preference-based EORTC-8D derived from EORTC QLQ-C30; and two published algorithms mapping QLQ-C30 onto EQ-5D. We further compare the performance of EORTC-8D and EORTC QLQ-C30 summary scores to determine whether the EORTC-8D maintains the desirable properties of the original measure. This paper seeks to inform researchers and policy makers in their choice of source of utility values and interpretation of these values regarding discrimination across severity groups, responsiveness and agreement.
Summary of measures

EQ-5D
EQ-5D has 5 dimensions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression) each with 3 levels of severity from no problems to severe problems (1).
The health state classification system describes 243 unique health states and utility values range from 1 to -0.594 for the UK value set collected in the Measuring and Valuing Health (MVH) study (10) .
EORTC QLQ-C30 and EORTC-8D
The QLQ-C30 is widely used in cancer clinical trials in Europe and Canada (15) 
Methods
Utility values were generated using the available preference weights for EQ-5D and EORTC-8D for each patient at each time point in the dataset. Mapped utility values were also estimated for each patient at each time point using published algorithms described below.
Estimating EQ-5D utilities by mapping QLQ-C30 onto EQ-5D
The easiest way to produce mapped estimates is to use published algorithms. Six published algorithms use mapping to produce utilities using EORTC QLQ-C30 data, two of which were used here (11;16) . The other four algorithms are not used here as one paper requires FACT data not available in our dataset (17) , one paper maps to patient TTO values rather than EQ-5D (18), one paper uses only females as their patient group (19) , and one paper does not publish the mapping function (20 to map onto EQ-5D. McKenzie and van der Pol also report regressions that predict EQ-5D
responses to each dimension rather than to a utility score, yet found that these performed worse and so they are not used here.
The second algorithm by Kontodimopoulos et al. (16) estimated OLS regressions on 48
patients with gastric cancer. Explanatory variables included in the model were selected using a stepwise inclusion procedure and the remaining variables were the physical functioning, emotional functioning and global health status scales.
Cancer patient dataset
The analysis was undertaken for a sample of patients newly diagnosed with multiple myeloma 
Analysis
Psychometric and statistical analyses were used to compare the utility estimates produced using different methods and EORTC QLQ-C30 summary scores.
Validity: Discrimination across different severity groups
Construct validity is examined by assessing ability to discriminate between patients with different levels of severity. It is important that a utility measure or method of producing utilities can discriminate correctly amongst groups of different severity as this determines whether the utility values measure an improvement in quality of life due to a health improvement in the condition of interest. The Karnofsky Performance Scale is reported by the doctor and classifies patients according to functional impairment typically using 10 point markers, where a score of 100 indicates that the patient is normal with no signs of disease and a score of 0 is equivalent to death (22) . As clinical severity is conceptually different to quality of life discrimination was also captured across different groups according to self-reported quality of life using item 30 from the EORTC QLQ-C30 ('How would you rate your overall quality of life during the past week? Please circle the number between 1 and 7 that best applies to you, 1=very poor and 7=excellent'). Discrimination was examined using the statistical significance of differences using an overall F-test from an ANOVA and the sensitivity of differences using standardised effect size (ES). ES is estimated using the difference in mean scores between two adjacent sub-groups of study participants with different levels of severity divided by the standard deviation of scores for the mildest of the two sub-groups. Utilities were also plotted for severity groups categorised according to the Karnofsky Performance Scale and selfreported quality of life.
Responsiveness to change over time
Responsiveness is the sensitivity of a measure to known changes in health over time. Here this is examined in terms of sensitivity to change in trial data before and after treatment across all study arms. Responsiveness was examined using floor and ceiling effects, standardised response mean (SRM), ES and t tests. Floor and ceiling effects report the percentage of patients in either full health or the most severe health state 'PITS', where a high percentage indicates that the measure is unable to capture either an improvement or deterioration in health respectively. Relative floor and ceiling effects are important as they indicate that one measure cannot distinguish whereas another can. SRM is the mean change score of a measure between two different time points divided by the standard deviation of the change score (23) . ES in this case is the mean change score of a measure between two different time points divided by the standard deviation of the score at baseline. Standardised response mean and effect size are generated to assess the responsiveness of the different methods between screening and cycle 9 of the trial and between screening and end of treatment. These points were chosen as screening represents the only period before treatment (n=604), cycle 9 represents the end of treatment for patients completing all 9 treatment cycles (n=283) whereas end of treatment includes respondents at the end of their treatment (n=406). Statistical significance of any difference is examined using t-tests. Utilities generated using each method were plotted by period to determine whether they show comparable movements in quality of life throughout the trial. All statistics were reported using all responses where observations were available for every measure of interest.
Correlation and agreement
The estimates produced using the different methods are compared using Pearson correlation coefficients and the intraclass correlation coefficient (ICC). ICC assesses the consistency of the methods given that they are all generating utility values on the same 1-0 full health-dead scale.
Differences across classification systems and preference weights
Further analysis was undertaken to determine why any differences in values were observed between EQ-5D and EORTC-8D. This analysis can also be used to highlight whether the measures have content validity for this patient group. If EQ-5D and EORTC-8D produce different values possible explanations include: classification system; preference weights for the classification system; recall period. The recall period is likely to explain some difference as EORTC-8D measures health during the past week whereas EQ-5D measures health today. This is an issue for research using qualitative analysis and is beyond the scope of this paper. Further analysis was here undertaken to explore differences due to the classification system and preference weights.
Differences in classification system were examined using Spearman rank correlations of each dimension of each measure. Observed frequencies of each dimension are also reported when each measure is at full health to determine differences across the measures in ability to detect a health improvement at the ceiling of the measure.
Differences in preference weights were analysed using different weightings for EQ-5D. Two alternative sets of EQ-5D utility weights were used here (24;25). The first alternative set of preference weights by Craig and Busschbach (25) were derived by remodelling the timetrade-off (TTO) values collected in the MVH study that were used to produce the standard UK value set (here referred to as the MVH value set) (10). The model was developed to deal with a criticism of how worse than dead responses were modelled to produce the UK MVH value set (25) . The second alternative set of preference weights by Yang el al. were estimated on TTO data collected in a separate study using a small UK general population sample (n=81) (24) .
Results
Discrimination
Severity groups were generated using the Karnofsky performance scale and overall quality of life (using a QLQ-C30 item). EORTC-8D had generally higher effect sizes than EORTC QLQ-C30 and similar effect sizes to EQ-5D (see Table 1 ). Mapped estimates using both methods had higher effect sizes than EQ-5D and the highest effect sizes when severity groups were divided by overall quality of life, most likely due to the inclusion of QLQ-C30 global health status in both mapping algorithms. The difference in scores across adjacent severity groups was statistically significant at the 1% level for all measures. The EORTC-8D had a narrower range of mean values across severity groups than EQ-5D (0.597 to 0.852 compared to 0.259 to 0.810 for severity groups defined using the Karnofsky performance scale). Despite these differences, the smaller standard deviation of EORTC-8D resulted in similar effect sizes to EQ-5D. Figure 1 parts a) and c) indicate that EORTC-8D values have a much shallower gradient than the other methods, showing smaller differences across different severity groups.
Responsiveness
The range of utility values covers the full severity range for EQ-5D and EORTC-8D, yet the mapped EQ-5D estimates do not reflect the full range of severity at the lower end (Table 2) .
EQ-5D and mapped EQ-5D estimates have a much larger utility range than EORTC-8D due to the differences in the utility ranges of the measures. EQ-5D and the Kontodimopoulos et al mapped estimates suffer from ceiling effects (12.2% and 11.4% respectively). EORTC QLQ-C30 summary scores also suffer from ceiling effects (up to 80.3% for one symptom summary score), yet the EORTC-8D does not.
The mapped estimates have values above 1 as the mapping algorithms used here were estimated using OLS, meaning that predictions are not constrained to 1. As EQ-5D values greater than 1 are impossible to obtain this raises the issue of whether we should censor All methods used to produce utility values show significant differences in utilities between screening and cycle 9 and between screening and end of treatment ( Table 2 der Pol mapped EQ-5D estimates follow a similar pattern to the EQ-5D, whereas the Kontodimopoulos estimates follow a similar pattern to EORTC-8D. observed EQ-5D is less than 0.5 compared to EQ-5D greater than or equal to.0.5, and a similar pattern has been previously observed in the mapping literature (26) .
Correlation and agreement
Utility values generated using each of the values have high correlation coefficients (Table 3) yet the mapped estimates are more highly correlated with EORTC-8D than EQ-5D. This is perhaps unsurprising given that the mapped estimates and EORTC-8D are all generated using QLQ-C30 responses, but has not been explored in the mapping literature previously.
Differences across classification system and preference weights
The above analysis demonstrates differences in EQ-5D and EORTC-8D utilities. EQ-5D and EORTC-8D dimensions are most highly correlated where expected, such as EQ-5D
pain/discomfort and EORTC-8D pain ( Table 4 ). The correlations are below 0.5 between all EQ-5D dimensions and EORTC-8D fatigue, nausea and constipation/diarrhoea dimensions and between EQ-5D self-care and all EORTC-8D dimensions. This suggests differences in the quality of life captured by the two classification systems for these dimensions. Table 5 summarises EORTC-8D responses when EQ-5D=1 meaning that the respondent is in full health, demonstrating that the EORTC-8D captures an impact on quality of life according to dimensions such as fatigue and physical functioning that are not captured in the EQ-5D for these patients. This is most noticeable for fatigue where 52.77% of observations at EQ-5D full health have fatigue in the EORTC-8D, similarly 45.71% of observations have problems in the physical functioning dimension. Table 6 summarises EQ-5D responses when EORTC-8D=1
meaning that the respondent is in full health, finding that the EQ-5D captures some differences in pain/discomfort and anxiety/depression not captured by EORTC-8D, but the proportion of these responses is small (14.08% and 9.23% respectively).
The use of alternative EQ-5D preference weights reduces the range and standard deviation of EQ-5D utility values and standard deviation and using the Craig and Bussbach weights raises the mean value (Table 7) . Mean change is smaller using these alternative preference weights (0.059 to 0.098, Table 7 ) than using the standard UK EQ-5D weights (MVH value set (0.100 to 0.189, Table 2 ). 
Discussion
Generic EQ-5D, condition-specific EORTC-8D and two published mapping algorithms were used to generate utility estimates for Multiple Myeloma patients in a clinical trial dataset. We observed differences in mean utilities and in mean change across time periods using the different methods, with the EQ-5D consistently showing the largest mean utility gain. However all methods were able to discriminate between severity groups measured using the Karnofsky Performance Scale and an overall quality of life item and were responsive. We further compared the performance of EORTC-8D to the EORTC QLQ-C30 measure it was derived from, finding that discriminative validity and responsiveness of EORTC-8D was comparable to the QLQ-C30 functioning and symptom summary scores, but inferior to the QLQ-C30 global quality of life summary score. The QLQ-C30 global quality of life score was excluded from the health state classification system of EORTC-8D as it is inappropriate for inclusion in a multiattribute preference-based measure, yet was included in both the McKenzie and van der Pol and Kontodimopoulos et al mapping algorithms and their discriminative validity and responsiveness may in part be attributed to this. Analyses have been conducted using one patient dataset containing patients with one type of cancer and this is a limitation of this research. Replicating these analyses using data for other cancer types is recommended.
The analysis has been performed using observations with no missing data for any of the approaches used to generate utilities or EORTC QLQ-C30 summary scores. However, high levels of missing data mean that the utilities are not representative of the entire trial sample, and this is important as the data may be missing for systematic reasons where patients in the poorest health are unable to complete the appropriate questionnaire. Missing values for the overall dataset do vary by method, where overall the Kontodimopoulos et al estimates has the smallest proportion of missing values (2.2%), followed by EQ-5D (2.8%), with the EORTC-8D (4.4%) and the McKenzie and van der Pol estimates (5.1%) having the largest proportions.
Mapping is advantageous as it enables EQ-5D utilities to be estimated when EQ-5D was not included in the trial. However these mapped values contain error and should be considered only as a second best alternative to including EQ-5D directly in the trial. Here the McKenzie and van der Pol algorithm (11) produced more accurate EQ-5D estimates than the Kondimopoulos et al algorithm (16) yet both have high mean absolute error. We suggest that EORTC-8D utilities are more accurate than these mapped estimates as they do not contain error. However NICE suggests that the mapped estimates should be presented in the main economic evaluation analyses and EORTC-8D utilities should be included in a separate analysis (6) . NICE further recommend that when using condition-specific measures such as EORTC-8D researchers should indicate the extent to which their choice of instrument has impacted on the valuations. Our findings suggest that the use of EORTC-8D would generate lower mean change in utilities with smaller standard deviation than the use of EQ-5D to generate utilities for the same cancer patient group.
NICE recommend using the same valuation methodology as the UK valuation of EQ-5D to ensure comparability to EQ-5D when using condition-specific measures to produce utilities for use in economic evaluation (6) . Yet differences between EQ-5D and EORTC-8D were observed despite the EORTC-8D using the same valuation methodology as the UK MVH valuation of the EQ-5D (10) . Further analysis suggested that some of the differences were due to the classification system yet some of the differences were due to the preference weights. The alternative EQ-5D preference weights produced closer utility estimates to the EORTC-8D utilities than the use of the standard UK EQ-5D weights (MVH value set).
Here we have not analysed the impact these differences have on QALY estimates. It is possible that the differences in utility values will have an impact on QALY estimates and change in QALY estimates, particularly where survival differs across interventions. Two studies have compared mapped estimates to direct EQ-5D estimates for use to generate QALYs in economic evaluation (11;12) . Although both studies found no significant difference between QALY estimates generated using mapping to EQ-5D and directly observed EQ-5D values, one of these studies found that incremental cost per QALY estimates differed across four interventions depending on whether mapped or directly observed EQ-5D values were used (12) . Research analysing the impact on QALY estimates from using generic or condition-specific preference-based measures is recommended.
EQ-5D is not always included in cancer trials, sometimes because it is thought to be inappropriate or unresponsive. In contrast, condition-specific measures are often included, as they are thought appropriate and responsive. Here EQ-5D has higher responsiveness than the condition-specific EORTC-8D and was also able to discriminate between severity groups using the Karnofsky Performance Scale and an overall quality of life item from the QLQ-C30.
This raises the issue of why it is thought the EQ-5D is inappropriate for capturing change in cancer patients. Our findings suggest it may be due to content validity, as here 12.2% of EQ-5D responses are at full health whereas for a large proportion of these observations the EORTC-8D captures problems on dimensions such as fatigue and physical functioning. This indicates problems with content validity, yet this can only be appropriately determined using qualitative analysis which is beyond the scope of this paper. This raises the issue of how to determine whether EQ-5D is inappropriate. Guidance suggests that it is not simply a question of ability to detect a change; content validity has an important role in the new US FDA guidance on patient reported outcomes for use in labelling claims (8) , and a recent report on economic evaluations in cancer found that EQ-5D did not contain all domains thought important for sensitivity in an outcome measure for cancer patients (7).
The recommendation of one generic measure such as the EQ-5D for use in all economic evaluations is advantageous for comparability, but raises issues of best practice when this measure is unavailable or inappropriate. Recommended alternatives are to use mapped estimates or other preference-based measures. Our analysis suggests that these methods are able to discriminate across severity groups and are responsive, but that the mean change and standard deviation across time periods or severity groups is affected by the alternative method used, and all methods produced lower mean change and standard deviation than the use of EQ-5D directly. Mapped estimates contain error and this will affect the accuracy of the utility estimates. In contrast, EORTC-8D estimates captured problems in quality of life at the upper end of the utility scale that were not captured by EQ-5D, but overall produced higher utility estimates and smaller mean change. The preference-based EORTC-8D performed comparably to the non-preference-based EORTC QLQ-C30 measure it was derived from. 
EQ-5D weights
Note: n<40 for Karnofsky Performance Scale<60 so is not reported for 1a) and 1d).
